The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors.
U. Keilholz
Honoraria - AstraZeneca
Research Funding - AstraZeneca
V. Moiseyenko
No relevant relationships to disclose
A. Makhson
Honoraria - Amgen; AstraZeneca; Lilly
V. Semiglazov
No relevant relationships to disclose
M. Learoyd
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
A. Saunders
Employment or Leadership Position - AstraZeneca
M. Stuart
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
S. Tjulandin
Consultant or Advisory Role - Novartis; Pfizer; Roche
Honoraria - AstraZeneca; GlaxoSmithKline; Sanofi